Evidence map›Paper›PMID 41624154›Full record

ArticleKidney diseases (Basel, Switzerland)

Influence of SGLT2i on Renal Progression in CKD Patients: A Multicenter Real-World Study in China.

Wen-Cong Guo, Li-Cong Su, Bin Wang, Zuo-Lin Li, Min Wu, Yi Wen, Meng-Chun Gong, Fan-Fan Hou, Bi-Cheng Liu, CRDS Study Investigators

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney diseases (Basel, Switzerland). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Wen-Cong GuoInstitute of Nephrology, Zhong Da Hospital, School of Medicine, Southeast University, Nanjing, China.
Li-Cong SuDivision of Nephrology, Nanfang Hospital, Southern Medical University; National Clinical Research Center for Kidney Disease; State Key Laboratory of Organ Failure Research; Guangdong Provincial Institute of Nephrology; Guangdong Provincial Key Laboratory of Renal Failure Research, Guangzhou, China.
Bin WangInstitute of Nephrology, Zhong Da Hospital, School of Medicine, Southeast University, Nanjing, China.
Zuo-Lin LiInstitute of Nephrology, Zhong Da Hospital, School of Medicine, Southeast University, Nanjing, China.
Min WuInstitute of Nephrology, Zhong Da Hospital, School of Medicine, Southeast University, Nanjing, China.
Yi WenInstitute of Nephrology, Zhong Da Hospital, School of Medicine, Southeast University, Nanjing, China.
Meng-Chun GongGMC Lab, School of Biomedical Engineering, Guangdong Medical University, Dongguan, China.
Fan-Fan HouDivision of Nephrology, Nanfang Hospital, Southern Medical University; National Clinical Research Center for Kidney Disease; State Key Laboratory of Organ Failure Research; Guangdong Provincial Institute of Nephrology; Guangdong Provincial Key Laboratory of Renal Failure Research, Guangzhou, China.
Bi-Cheng LiuInstitute of Nephrology, Zhong Da Hospital, School of Medicine, Southeast University, Nanjing, China.
CRDS Study Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Although large randomized control trials have established the renal benefits of sodium-glucose cotransporter-2 inhibitors (SGLT2is) in chronic kidney disease (CKD), real-world evidence in Chinese CKD populations remains scarce. Here we report a multicenter real-world retrospective cohort study of SGLT2i use in hospitalized CKD patients in China. Methods: We enrolled 155,053 adults with CKD from the China Renal Data System (CRDS) databases (January 2002-January 2023). We included patients treated with SGLT2i for at least 3 months. SGLT2i users and nonusers were matched (1:2) using propensity score matching (PSM). The main outcomes included renal, safety, and clinical outcomes. Renal outcomes included the first occurrence of CKD progression, end-stage kidney disease (ESKD), or composite outcomes. Multivariable Cox regression models and cumulative incidence were estimated post-PSM. Results: Overall, the core analysis included 1,477 SGLT2i users and 2,674 nonusers. The progression of CKD (HR 0.81, 95% confidence interval [CI] 0.69-0.95, Conclusion: These findings suggest that SGLT2i offers substantial renal and cardiovascular benefits for Chinese CKD patients.

Indexed as

Cardiovascular diseasesChronic kidney diseaseEnd-stage kidney diseaseMetabolismReal-world studySGLT2i

Identifiers

PMID41624154
PMCPMC12858204

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.